Delving into the Latest Updates on ZIFA-01 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesRespiratory Diseases

Active Indication

Pulmonary EmbolismVenous ThromboembolismThrombosis

Inactive Indication-

Originator Organization

Tianjin Institute of Pharmaceutical Research Co., Ltd.

Active Organization

Tianjin Institute of Pharmaceutical Research Co., Ltd.

Peking University

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and pharmacokinetic characteristics of Zifa01 after multiple oral administration in healthy Chinese subjects. Secondary objective: To evaluate the pharmacodynamic characteristics (changes in coagulation indicators) of Zifa01 after multiple oral administration in healthy Chinese subjects.

Start Date14 Aug 2019

Sponsor / Collaborator

Tianjin Institute of Pharmaceutical Research Co., Ltd.

ChiCTR1900022783

/ SuspendedPhase 1IIT

A single-center, phase I clinical study evaluating the effects of food on the pharmacokinetics of ZIFA01 tablets

Start Date05 May 2019

Sponsor / Collaborator

Peking University First Hospital

100 Clinical Results associated with ZIFA-01

Login to view more data

100 Translational Medicine associated with ZIFA-01

Login to view more data

100 Patents (Medical) associated with ZIFA-01

Login to view more data

100 Deals associated with ZIFA-01

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Embolism	Phase 1	China	Tianjin Institute of Pharmaceutical Research Co., Ltd.	18 Jul 2018
Venous Thromboembolism	Phase 1	China	Tianjin Institute of Pharmaceutical Research Co., Ltd.	18 Jul 2018
Thrombosis	Preclinical	China	Peking University	-